Bridgebio Pharma (BBIO)
NASDAQ:BBIO
Want to see BBIO full AI Analyst Report?
Total Valuation
BridgeBio Pharma has a market cap or net worth of $12.79B. The enterprise value is $15.87B.
Market Cap$12.79B
Enterprise Value$15.87B
Share Statistics
BridgeBio Pharma has 195,861,240 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding195,861,240
Owned by Insiders13.46%
Owned by Institutions38.63%
Financial Efficiency
BridgeBio Pharma’s return on equity (ROE) is 0.35 and return on invested capital (ROIC) is -108.46%.
Return on Equity (ROE)0.35
Return on Assets (ROA)-0.78
Return on Invested Capital (ROIC)-108.46%
Return on Capital Employed (ROCE)-0.88
Revenue Per Employee692.52K
Profits Per Employee-999.90K
Employee Count725
Asset Turnover0.54
Inventory Turnover1.06
Valuation Ratios
The current PE Ratio of BridgeBio Pharma is ―. BridgeBio Pharma’s PEG ratio is -0.65.
PE Ratio―
PS Ratio30.05
PB Ratio-7.27
Price to Fair Value-7.27
Price to FCF-33.75
Price to Operating Cash Flow-29.93
PEG Ratio-0.65
Income Statement
In the last 12 months, BridgeBio Pharma had revenue of 502.08M and earned -729.31M in profits. Earnings per share was -3.79.
Revenue502.08M
Gross Profit473.81M
Operating Income-569.09M
Pretax Income-734.99M
Net Income-729.31M
EBITDA-672.88M
Earnings Per Share (EPS)-3.79
Cash Flow
In the last 12 months, operating cash flow was -443.95M and capital expenditures -10.17M, giving a free cash flow of -454.12M billion.
Operating Cash Flow-443.95M
Free Cash Flow-454.12M
Free Cash Flow per Share-2.32
Dividends & Yields
BridgeBio Pharma pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.69
52-Week Price Change100.97%
50-Day Moving Average71.35
200-Day Moving Average65.65
Relative Strength Index (RSI)40.64
Average Volume (3m)2.65M
Important Dates
BridgeBio Pharma upcoming earnings date is Jul 30, 2026, After Close (Confirmed).
Last Earnings DateMay 7, 2026
Next Earnings DateJul 30, 2026
Ex-Dividend Date―
Financial Position
BridgeBio Pharma as a current ratio of 2.62, with Debt / Equity ratio of -149.19%
Current Ratio2.62
Quick Ratio2.52
Debt to Market Cap0.18
Net Debt to EBITDA-3.21
Interest Coverage Ratio-10.72
Taxes
In the past 12 months, BridgeBio Pharma has paid 555.00K in taxes.
Income Tax555.00K
Effective Tax Rate>-0.01
Enterprise Valuation
BridgeBio Pharma EV to EBITDA ratio is -25.63, with an EV/FCF ratio of -38.58.
EV to Sales34.35
EV to EBITDA-25.63
EV to Free Cash Flow-38.58
EV to Operating Cash Flow-38.67
Balance Sheet
BridgeBio Pharma has $940.19M in cash and marketable securities with $3.38B in debt, giving a net cash position of -$2.44B billion.
Cash & Marketable Securities$940.19M
Total Debt$3.38B
Net Cash-$2.44B
Net Cash Per Share-$12.48
Tangible Book Value Per Share-$10.67
Margins
Gross margin is 93.78%, with operating margin of -113.35%, and net profit margin of -145.26%.
Gross Margin93.78%
Operating Margin-113.35%
Pretax Margin-146.39%
Net Profit Margin-145.26%
EBITDA Margin-134.02%
EBIT Margin-135.81%
Analyst Forecast
The average price target for BridgeBio Pharma is $106.35, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$106.35
Price Target Upside38.57% Upside
Analyst ConsensusStrong Buy
Analyst Count18
Revenue Growth Forecast355.17%
EPS Growth Forecast-6.09%